5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
A guide to PT-141 (bremelanotide) dosing, safety monitoring, drug interactions, and activity considerations specifically for adults aged 65 and older, with primary-source citations throughout.
A clinical review of bremelanotide's effects on adolescent development, including hypothalamic-pituitary axis interference, melanocortin receptor biology, and why PT-141 has no approved or studied role in patients ages 12 to 17.
A look at bremelanotide's pharmacology, safety, and emerging use in adults 65 and older, covering age-related physiology, trial data, dosing cautions, and clinical decision points.
Bremelanotide (PT-141) is FDA-approved only for premenopausal adult women. This HealthRX.com clinical guide explains why it must not be administered to children under 12, the pharmacology behind that restriction, and what caregivers should do instead.
A clinical review of bremelanotide (PT-141) off-label use in pediatric patients under age 12, covering the regulatory status, pharmacology, safety data, and why prescribing it to young children has no established evidence base.